Influencia de la vacunación antigripal y la comorbilidad en la evolución de los pacientes hospitalizados por COVID-19 / Influence of influenza vaccine and comorbidity on the evolution of hospitalized COVID-19 patients

Antecedentes y objetivo:El brote de la enfermedad COVID-19 está evolucionando en todo el mundo. El objetivo del estudio es evaluar la asociación entre la vacunación antigripal y el riesgo de mortalidad en pacientes con COVID-19 hospitalizados, así como otros factores de riesgo.Materiales y métodos:Estudio observacional retrospectivo. Se realizó entre pacientes hospitalizados con COVID-19 del Hospital La Mancha Centro entre el 5 y el 25 de marzo de 2020. Utilizamos una regresión logística multivariable para explorar la asociación entre la vacunación antigripal y la mortalidad por COVID y otros factores de riesgo.Resultados:Se incluyeron 410 pacientes. La vacunación antigripal no tuvo efecto entre los pacientes hospitalizados por COVID-19 (OR: 1,55 [IC 95%; 0,96-2,48; p = 0,071]). El aumento de la mortalidad intrahospitalaria se asoció con edad avanzada (OR: 1,05 [IC 95%; 1,02-1,07]), por cada aumento de año; p < 0,001, Charlson ≥ 3 (OR: 1,84 [IC 95%; 1,07-3,15, p = 0,027]) e insuficiencia cardíaca al ingreso (OR: 6 [IC 95%; 1,6-21,7; p = 0,007]).Conclusiones:La vacuna antigripal no tuvo efecto en la evolución de pacientes hospitalizados por COVID-19. Los factores de riesgo identificados fueron la edad avanzada, mayor comorbilidad e insuficiencia cardíaca al ingreso. (AU)

Background and objective:The COVID-19 coronavirus disease outbreak is evolving around the world. The aim of this study is to evaluate the association between influenza vaccination and the risk of mortality in hospitalized COVID-19 patients, as well as other risk factors.Materials and methods:Retrospective observational study. This study was conducted among hospitalized patients with COVID-19 at Hospital La Mancha Centro between March 5 and 25, 2020. Information on influenza vaccination was extracted from electronic medical records. We used a multivariate logistic regression to explore the association between influenza vaccination and mortality from COVID and other risk factors.Results:410 patients were included. Influenza vaccine had no effect among COVID-19 hospitalized patients [OR: 1.55 (95%CI: 0.96 – 2.48; p=0.071)]. Increasing hospital mortality was associated with older age [OR: 1.05 (95% CI 1.02–1.07), per year increase; p<0.001)], Charlson ≥3 [OR: 1.84 (95%CI: 1.07-3.15, p=0.027)] and heart failure on admission [OR: 6 (IC95%: 1.6 – 21.7; p=0.007)]Conclusions:Influenza vaccine had no effect among COVID-19 hospitalized patients. The risk factors identified were older age, higher comorbidity and heart failure on admission. (AU)

Influence of influenza vaccine and comorbidity on the evolution of hospitalized COVID-19 patients⋆.

Background and objective: The COVID-19 coronavirus disease outbreak is evolving around the world. Objective: To evaluate the associations between influenza vaccination and other factors and the risk of mortality in hospitalized COVID-19 patients. Materials and methods: Retrospective observational study. This study was conducted among hospitalized patients with COVID-19 at Hospital La Mancha Centro between March 5 and 25, 2020. Information on influenza vaccination was extracted from electronic medical records. We used a multivariate logistic regression to explore the association between influenza vaccination and mortality from COVID and other risk factors. Results: 410 patients were included. Influenza vaccine had no effect among COVID-19 hospitalized patients [OR: 1.55 (95%CI: 0.96-2.48; p = 0.071)]. Increasing hospital mortality was associated with older age [OR: 1.05 (95% CI 1.02-1.07), per year increase; p < 0.001)], Charlson ≥3 [OR: 1.84 (95%CI: 1.07-3.15, p = 0.027)] and heart failure on admission [OR: 6 (IC95%: 1.6-21.7; p = 0.007)]. Conclusions: Influenza vaccine had no effect among COVID-19 hospitalized patients. The risk factors identified were older age, higher comorbidity and heart failure on admission.

Antecedentes y objetivo: El brote de la enfermedad COVID-19 está evolucionando en todo el mundo. Objetivo: Evaluar la asociación de la vacunación antigripal y otros factores y el riesgo de mortalidad en pacientes con COVID-19 hospitalizados. Materiales y métodos: Estudio observacional retrospectivo. Se realizó entre pacientes hospitalizados con COVID-19 del Hospital La Mancha Centro entre el 5 y el 25 de marzo de 2020. Utilizamos una regresión logística multivariable para explorar la asociación entre la vacunación antigripal y la mortalidad por COVID y otros factores de riesgo. Resultados: Se incluyeron 410 pacientes. La vacunación antigripal no tuvo efecto entre los pacientes hospitalizados por COVID-19 [OR: 1,55 (IC95%: 0,96­2,48; p = 0,071)]. El aumento de la mortalidad intrahospitalaria se asoció con edad avanzada [OR: 1,05, (IC95%: 1,02­1,07), por cada aumento de año; p < 0.001)], Charlson ≥ 3 [OR: 1,84 (IC95%: 1,07­3,15, p = 0,027)] e insuficiencia cardíaca al ingreso [OR: 6 (IC95%: 1,6­21,7; p = 0,007)]. Conclusiones: La vacuna antigripal no tuvo efecto en la evolución de pacientes hospitalizados por COVID-19. Los factores de riesgo identificados fueron la edad avanzada, mayor comorbilidad e insuficiencia cardíaca al ingreso.

Factores de riesgo de mortalidad en pacientes mayores de 65 años hospitalizados por COVID-19 / Risk factors for mortality in patients over 65 years old hospitalized by COVID-19

Antecedentes y objetivoCOVID-19 es una enfermedad causada por el coronavirus 2 del síndrome respiratorio agudo grave (SARS-CoV-2), que ha provocado una pandemia que sufrimos en la actualidad.Objetivo:identificar factores asociados con la mortalidad en pacientes de 65 años o más hospitalizados por COVID-19.Materiales y métodos: Estudio observacional retrospectivo. Incluimos pacientes de edad ≥65 años ingresados por COVID-19 entre el 5 y el 25 de marzo del 2020. Utilizamos el análisis bivariante y la regresión logística multivariante para determinar los factores de riesgo asociados a la mortalidad hospitalaria.Resultados: Se incluyeron 277 pacientes en el presente estudio. El análisis bivariante mostró diferencias significativas (p<0,05) entre fallecidos y supervivientes: edad, mayor dependencia y comorbilidad, antecedentes de cardiopatía isquémica, insuficiencia renal y neoplasias no hematológicas, insuficiencia cardiaca durante el ingreso, leucocitosis, valores elevados de creatinina, PCR, GOT y troponina Ic, linfopenia, y disminución de SatO2 y pH sanguíneo. La regresión logística multivariante reveló que la edad ≥65 años [OR: 4,23 (IC 95%: 1,43-12,52); p=0,009], linfopenia <1.000/μl [OR: 2,36 (IC 95%: 1,07-5,20); p=0,033], creatinina>1,2mg/dl [OR: 3,08 (IC 95%: 1,37-6,92); p=0,006], SatO2 <90% [OR: 2,29 (IC 95%: 1,01-5,21); p=0,049] y la troponina Ic>11ng/ml [OR: 2,32 (IC 95%: 1,04-5,16); p=0,040] se asociaron independientemente con mayor mortalidad hospitalaria.Conclusiones: La edad avanzada, linfopenia, SatO2 <90%, valores elevados de creatinina y troponina Ic se asociaron independientemente con mayor mortalidad en pacientes hospitalizados con COVID-19, lo que podría ayudar a los médicos a identificar a los pacientes con mal pronóstico para su manejo y tratamiento. (AU)

Background and objectiveCOVID-19 is a disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has caused a global pandemic that we are currently suffering from.Objective: to identify factors associated with the death of patients aged 65 years or older hospitalized for COVID-19.Materials and methods: Retrospective cohort study. We included patients aged 65 years or older who were hospitalized for COVID-19 and dead o discharged between March 5 and 25, 2020. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death.Results: 277 patients were included in this study. The bivariate analysis showed significant differences (p<0.05) between survivors and non survivors: age, increased dependence and comorbidity, history of ischemic heart disease, renal failure and non-hematological neoplasms, heart failure during admission, leukocytosis, elevated creatinine, PCR, GOT and troponin Ic values, lymphopenia, and decreased blood pH and SatO2. Multivariate logistic regression revealed that age ≥65 years (OR: 4.23 (95% CI: 1.43-12.52; p=0.009), lymphopenia <1000/μL (OR: 2.36 (95% CI: 1.07-5.20; p=0.033), creatinine>1.2mg/dL (OR: 3.08 (95% CI: 1.37-6.92; p=0.006), SatO2 <90% (OR: 2.29 (95% CI: 1.01-5.21; p=0.049) and troponin Ic>11ng/mL (OR: 2.32 (95% CI: 1.04-5.16; p=0.040) were independently associated with higher hospital mortality. Conclusions: Older age, lymphopenia, SatO2 <90%, elevated creatinine and troponin Ic values were independently associated with higher mortality in hospitalized patients with COVID-19, these factors could help clinicians to identify patients with poor prognosis. (AU)

Influence of influenza vaccine and comorbidity on the evolution of hospitalized COVID-19 patients. / Influencia de la vacunación antigripal y la comorbilidad en la evolución de los pacientes hospitalizados por COVID-19.

BACKGROUND AND OBJECTIVE: The COVID-19 coronavirus disease outbreak is evolving around the world. The aim of this study is to evaluate the association between influenza vaccination and the risk of mortality in hospitalized COVID-19 patients, as well as other risk factors. MATERIALS AND METHODS: Retrospective observational study. This study was conducted among hospitalized patients with COVID-19 at Hospital La Mancha Centro between March 5 and 25, 2020. Information on influenza vaccination was extracted from electronic medical records. We used a multivariate logistic regression to explore the association between influenza vaccination and mortality from COVID and other risk factors. RESULTS: 410 patients were included. Influenza vaccine had no effect among COVID-19 hospitalized patients [OR: 1.55 (95%CI: 0.96 - 2.48; p=0.071)]. Increasing hospital mortality was associated with older age [OR: 1.05 (95% CI 1.02-1.07), per year increase; p<0.001)], Charlson ≥3 [OR: 1.84 (95%CI: 1.07-3.15, p=0.027)] and heart failure on admission [OR: 6 (IC95%: 1.6 - 21.7; p=0.007)] CONCLUSIONS: Influenza vaccine had no effect among COVID-19 hospitalized patients. The risk factors identified were older age, higher comorbidity and heart failure on admission.

[Risk factors for mortality in patients over 65 years old hospitalized by COVID-19]. / Factores de riesgo de mortalidad en pacientes mayores de 65 años hospitalizados por COVID-19.

BACKGROUND AND OBJECTIVE: COVID-19 is a disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has caused a global pandemic that we are currently suffering from. OBJECTIVE: to identify factors associated with the death of patients aged 65 years or older hospitalized for COVID-19. MATERIALS AND METHODS: Retrospective cohort study. We included patients aged 65 years or older who were hospitalized for COVID-19 and dead o discharged between March 5 and 25, 2020. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death. RESULTS: 277 patients were included in this study. The bivariate analysis showed significant differences (p<0.05) between survivors and non survivors: age, increased dependence and comorbidity, history of ischemic heart disease, renal failure and non-hematological neoplasms, heart failure during admission, leukocytosis, elevated creatinine, PCR, GOT and troponin Ic values, lymphopenia, and decreased blood pH and SatO2. Multivariate logistic regression revealed that age ≥65 years (OR: 4.23 (95% CI: 1.43-12.52; p=0.009), lymphopenia <1000/µL (OR: 2.36 (95% CI: 1.07-5.20; p=0.033), creatinine>1.2mg/dL (OR: 3.08 (95% CI: 1.37-6.92; p=0.006), SatO2 <90% (OR: 2.29 (95% CI: 1.01-5.21; p=0.049) and troponin Ic>11ng/mL (OR: 2.32 (95% CI: 1.04-5.16; p=0.040) were independently associated with higher hospital mortality. CONCLUSIONS: Older age, lymphopenia, SatO2 <90%, elevated creatinine and troponin Ic values were independently associated with higher mortality in hospitalized patients with COVID-19, these factors could help clinicians to identify patients with poor prognosis.

Electrocardiographic signs of acute right ventricular hypertrophy in patients with COVID-19 pneumonia: A clinical case series.

This paper reports 6 cases of patients affected by coronavirus disease 2019 bilateral pneumonia with associated acute respiratory distress associated and signs of acute right ventricular hypertrophy on electrocardiography despite the absence of acute pulmonary embolism or signs of severe pulmonary hypertension on transthoracic echocardiography. These cases suggest a possible connection between acute elevated right ventricular afterload and acute respiratory distress in patients affected by SARS-CoV-2.

Síndrome de Tako-Tsubo como primera manifestación cardiaca en la enfermedad de Steinert / Tako-Tsubo syndrome as first cardiac manifestation in Steinert's disease

No disponible

Alteraciones electrocardiográficas transitorias durante un episodio de hipoglucemia / Transient electrocardiographic abnormalities during hypoglycemia

No disponible

Mujer joven con dolor torácico posparto / Young woman with postpartum chestpain

No disponible

Infarto anterior y anomalía coronaria: una rara asociación / Anterior infarction and coronary artery anomaly: a rare association

No disponible